PGXL’s VP of Laboratory Operations, Dr. Kristen Reynolds, is quoted extensively in Pain Pathways magazine’s look at pharmacogenetic options for pain treatment.
I think genetic diagnostics put into clinical use will eventually be come a new standard of care. In the pain management field, many of the drugs prescribed are opioids, which only work if the liver can activate them. If a patient ’s liver can’t activate the medication, then the patient is basically taking a drug that will never work and continues to suffer from inadequate pain relief.
If you haven’t seen Pain Pathways, you should give it a look. It’s a well-executed and lively magazine that connects people suffering chronic pain with solutions and inspiration.